Cagrilintide

People run it for fat loss, the same goal as the GLP-1 drugs — but it gets there through amylin rather than GLP-1, so the felt experience is described as a steadier, more “full and satisfied” fullness than the sharp food-noise shutoff of semaglutide or tirzepatide. Solo it’s a moderate-strength weight-loss shot. Its real draw is as the partner peptide: pair it with a GLP-1 and the two appetite systems add together.

The whole pitch is that it’s a different switch. Amylin is a hormone your pancreas already co-releases with insulin after a meal — cagrilintide is a long-acting copy of it, engineered to last about a week per shot. Because it isn’t a GLP-1, it doesn’t compete for the same receptor; it layers on top. That’s the entire logic of the famous cagrilintide + semaglutide combination the community watches closely: amylin satiety plus GLP-1 satiety, two signals instead of one, with the combination trial data landing in the same 20%-plus weight-loss territory people associate with the strongest drugs in the class.

An amylin-receptor agonist — a distinct pathway from the GLP-1/GIP/glucagon axis the rest of the fat-loss peptides work. Amylin signals satiety to the hindbrain, slows gastric emptying so a meal sits longer, and suppresses glucagon (blunting the post-meal sugar release from the liver). The net effect is eating less and feeling full sooner, by a different route than GLP-1’s. Mechanistic work points to amylin receptors in the brain (the AMY1/AMY3 subtypes) as where the bodyweight effect is actually driven. Because amylin and GLP-1 hit separate receptors, their satiety effects are additive rather than redundant — which is the mechanistic basis for the combination.

The same GI profile as the rest of the fat-loss class: nausea is the most common, with vomiting, constipation, and diarrhea behind it — all worst during titration and easing as the dose settles. Unlike retatrutide, there’s no signature glucagon-driven heart-rate bump here, since it doesn’t touch the glucagon receptor as an agonist. Injection-site reactions show up. The combination with a GLP-1 stacks both drugs’ GI effects, which is the main reason both are titrated slowly. The usual class-wide concern — muscle loss with rapid weight loss — applies, so protein and training dominate the sane protocols. It’s investigational, so the long-term safety picture is still filling in.

This is the peptide whose whole story is a stack. The defining pairing is with a GLP-1 like semaglutide — and the reason it works is that amylin and GLP-1 are different satiety pathways hitting different receptors, so their effects add rather than overlap. GLP-1 drives one arm of appetite suppression and insulin/glucose handling; amylin drives a separate satiety-and-slowed-emptying arm and suppresses glucagon. Two signals, two receptors, one combined effect — which is why the combination beats either drug run alone. The supporting work is the same as any aggressive cut: high protein, resistance training, electrolytes.